Literature DB >> 30061052

Progress toward a transmission-blocking vaccine against malaria.

Tomoko Ishino1, Takafumi Tsuboi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30061052     DOI： 10.1016/S1473-3099(18)30358-X

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  5 in total

1.  Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice.

Authors:  Myriam Arévalo-Herrera; Kazutoyo Miura; Eduardo Solano; Juan Sebastián Ramírez; Carole A Long; Giampietro Corradin; Sócrates Herrera
Journal:  Vaccine       Date:  2021-11-19       Impact factor: 3.641

2.  Expression and purification optimization of an N-terminal Pfs230 transmission-blocking vaccine candidate.

Authors:  Shwu-Maan Lee; Jordan Plieskatt; Seetha Krishnan; Monika Raina; Rakeshkumar Harishchandra; C Richter King
Journal:  Protein Expr Purif       Date:  2019-04-10       Impact factor: 1.650

3.  The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate.

Authors:  Shwu-Maan Lee; Yimin Wu; John M Hickey; Kazutoyo Miura; Neal Whitaker; Sangeeta B Joshi; David B Volkin; C Richter King; Jordan Plieskatt
Journal:  Malar J       Date:  2019-11-08       Impact factor: 2.979

4.  Immunoreactivity of Sera From Low to Moderate Malaria-Endemic Areas Against Plasmodium vivax rPvs48/45 Proteins Produced in Escherichia coli and Chinese Hamster Ovary Systems.

Authors:  Myriam Arévalo-Herrera; Kazutoyo Miura; Nora Cespedes; Carlos Echeverry; Eduardo Solano; Angélica Castellanos; Juan Sebastián Ramirez; Adolfo Miranda; Andrey V Kajava; Carole Long; Giampietro Corradin; Sócrates Herrera
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

5.  A C-terminal Pfs48/45 malaria transmission-blocking vaccine candidate produced in the baculovirus expression system.

Authors:  Shwu-Maan Lee; John M Hickey; Kazutoyo Miura; Sangeeta B Joshi; David B Volkin; C Richter King; Jordan L Plieskatt
Journal:  Sci Rep       Date:  2020-01-15       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.